BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23820731)

  • 1. A new model to evaluate Raf signaling in hematopoietic cells.
    Okuda K
    Int J Oncol; 2013 Sep; 43(3):903-10. PubMed ID: 23820731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician Education: The Erythropoietin Receptor and Signal Transduction.
    Yoshimura A; Arai K
    Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation.
    Calvo V; Wood M; Gjertson C; Vik T; Bierer BE
    Eur J Immunol; 1994 Nov; 24(11):2664-71. PubMed ID: 7957559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactive oxygen species generated by hematopoietic cytokines play roles in activation of receptor-mediated signaling and in cell cycle progression.
    Iiyama M; Kakihana K; Kurosu T; Miura O
    Cell Signal; 2006 Feb; 18(2):174-82. PubMed ID: 15982852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
    Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
    Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.
    Okuda K; D'Andrea A; Etten RA; Griffin JD
    J Clin Invest; 1997 Oct; 100(7):1708-15. PubMed ID: 9312168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
    Chen J; Jacobs-Helber SM; Barber DL; Sawyer ST
    Exp Cell Res; 2004 Aug; 298(1):155-66. PubMed ID: 15242770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury.
    Li X; Gonias SL; Campana WM
    Glia; 2005 Sep; 51(4):254-65. PubMed ID: 15812815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
    Miura O; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N
    Blood; 1994 Sep; 84(5):1501-7. PubMed ID: 8068943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion.
    Jin A; Kurosu T; Tsuji K; Mizuchi D; Arai A; Fujita H; Hattori M; Minato N; Miura O
    Oncogene; 2006 Jul; 25(31):4332-40. PubMed ID: 16518411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells.
    Arai A; Aoki M; Weihua Y; Jin A; Miura O
    Cell Signal; 2006 Dec; 18(12):2162-71. PubMed ID: 16781119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
    Negre O; Fusil F; Henri A; Villette JM; Leboulch P; Beuzard Y; Payen E
    Exp Hematol; 2008 Apr; 36(4):412-23. PubMed ID: 18295963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the erythropoietin receptor on glioma cells reduces tumour growth.
    Pérès EA; Valable S; Guillamo JS; Marteau L; Bernaudin JF; Roussel S; Lechapt-Zalcman E; Bernaudin M; Petit E
    Exp Cell Res; 2011 Oct; 317(16):2321-32. PubMed ID: 21749867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals.
    Bose C; Udupa KB
    Am J Physiol Cell Physiol; 2008 Aug; 295(2):C394-405. PubMed ID: 18550701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine phosphorylation of the erythropoietin receptor: role for differentiation and mitogenic signal transduction.
    Gobert S; Porteu F; Pallu S; Muller O; Sabbah M; Dusanter-Fourt I; Courtois G; Lacombe C; Gisselbrecht S; Mayeux P
    Blood; 1995 Jul; 86(2):598-606. PubMed ID: 7541671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway.
    Shin SY; Rath O; Choo SM; Fee F; McFerran B; Kolch W; Cho KH
    J Cell Sci; 2009 Feb; 122(Pt 3):425-35. PubMed ID: 19158341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.